All articles by Amit Thadani
Amit Thadani
Infosys to acquire Danish life science consultancy firm for €110m
The acquisition enables Infosys to provide the global life sciences companies with cloud-first digital platforms and data, strengthen its life sciences capabilities and expand its footprint across Europe
GenScript, ACT Therapeutics partner to develop new CAR-T Cell therapies
GenScript ProBio will support ACT therapeutics’ CAR-T Platform (ACT platform), an immune cell-based cell and gene therapy technology that leverages virus vectors to target cancer antigens
Roche licenses Ionis’ investigational therapy for rare kidney disease
Ionis will receive $55m from Roche, in exchange for licensing IONIS-FB-LRx and achieving a development milestone in the GOLDEN study
Vertex to acquire T1D therapeutics maker ViaCyte for $320m
The agreement follows the US Food and Drug Administration (FDA) lifting the clinical hold on the Phase 1/2 clinical trial of VX-880, a T1D therapy developed by Vertex
ADC Therapeutics, Sobi enter into license deal for Zynlonta
As per the agreement, the companies will develop and market Zynlonta for all hematologic and solid tumour indications, outside of the US, Greater China, Singapore and Japan
SIGA’s Tecovirimat approved in UK to treat complications after smallpox vaccination
The UK health regulator indicated Tecovirimat for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications, after vaccination against smallpox in adults and children
Emergent, Ridgeback partner to boost access to Ebola drug Ebanga
Emergent will manufacture, sell, and distribute Ebanga in the US and Canada, while Ridgeback will serve as the global access partner, and will ensure the drug is available to patients in endemic countries free of charge
Boehringer, Evotec and bioMérieux form new JV to fight AMR
The three companies formed a joint venture, dubbed Aurobac Therapeutics, which will develop both next-generation antimicrobials and diagnostics against AMR
Bruker rolls out new NMR test to support research on Long Covid
PhenoRisk PACS RuO will support research on samples collected from people who survived acute SARS-CoV-2 infection, called Post-Acute Covid Syndrome (PACS), or ‘Long Covid’ syndrome
Sanofi to distribute 30 critical medicines across 40 low-income countries
Impact includes insulin, glibenclamide and oxaliplatin, and other medicines to fight a wide range of areas including diabetes, cardiovascular disease, tuberculosis, malaria and cancer